ClinicalTrials.gg
TerminatedNCT00585312CHIPUpdated Feb 21, 2021Results posted

Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

A Phase 3 interventional study of Celecoxib and Placebo in Adenomatous Polyposis Coli, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 43 sites in 14 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Prevention

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.

Enrollment
7th of 27
106 · median 42
Started
2006
with 1 other
Phase 3
3 of 39
1 open now
Registered
5th of 39
by date

Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 3, and was the 5th registered.

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Open to participants now

12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Adenomatous Polyposis Coli with a site in United States, or all of them as a file.
02

Study summary

To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).

Read the detailed description

Per DMC recommendation, the study was terminated early (31Oct2013) due to low enrollment and low endpoint accumulation rate. No safety concerns were involved in the decision to terminate the study.

03

Conditions studied

  • Adenomatous Polyposis Coli

Keywords

  • FAP
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 10-17 years
  • Confirmed deleterious FAP genotype based on central genetic testing or personal history ot >2 colorectal adenomas and a parent with the diagnosis of FAP and either A, B or C below A: Non-attenuated FAP genotype B: Attenuated FAP genotype and a personal history of colorectal adenomas and a first degree relative with FAP C: No genotype identified with a personal history of > 2 adenomas and have a parent with FAP
  • Less than 30 polyps, which need to be removed to render the colon polyp-free before study drug can be given

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of attenuated FAP based on central genetic testing in the absence of a personal history of >2 colorectal adenomas and a first degree relative (parent or sibling) with FAP.
  • Sensitivity to COX-2 inhibitors
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Celecoxib

    celecoxib, 16 mg/kg/day, for 5 years

    Drug: Celecoxib

  • Placebo comparator
    Placebo

    Masked, placebo comparator

    Drug: Placebo

Interventions

  • celecoxib, 16 mg/kg/day, for 5 years

    Also known as: celebrex, SC-58635

  • DrugPlacebo

    Masked, placebo comparator

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression

    Time to disease progression was defined as the time from randomization to the earliest occurrence of one or more of the following events: 1. Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps); or 2. Diagnosis of colorectal malignancy (ColMal).

    Time frame: 5 years

Secondary outcomes

  1. Time to Treatment Failure

    Time to treatment failure was defined as time from randomization to the earliest occurrence of one or more of the following: * Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps), or * Diagnosis of colorectal malignancy (ColMal), or * Treatment related dropout (DO). The treatment related dropout was defined as insufficient clinical response, progression of disease, death, adverse event, treatment-related laboratory abnormality, subject no longer willing to participate in study, and other reasons that might be related to treatment as determined by treating physicians in a blind fashion before database release.

    Time frame: 5 years

  2. Total Number of Colorectal Polyps

    Total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5 cumulatively. Weighted total number of colorectal polyps over Years 1 - 5 cumulatively was defined as the total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5, divided by the number of colonoscopies that the participant had during the study.

    Time frame: Years 1 - 5

  3. Colorectal Polyp Burden

    The polyp burden was defined as the sum of the largest diameters of all polyps (\>2 mm in size) over Years 1 - 5 cumulatively. Weighted colorectal polyp burden over Years 1 - 5 cumulatively was defined as the polyp burden over Years 1 - 5 divided by the number of colonoscopies that the participant had during the study.

    Time frame: Years 1 - 5

07

Results

Posted Nov 2, 2014
Limitations and caveats
The study was early terminated and, due to the low number of participants, no efficacy analysis was performed. Only descriptive statistics was performed.

Participant flow

A total of 305 participants were screened, whereof 106 were randomized into the study, and of whom 101 took at least 1 dose of study drug. The clinical study was conducted in 18 centers across 13 countries: Belgium, Czech Republic, Hong Kong, Hungary, Israel, Italy, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom, and United States.

Participant flow — Overall Study
MilestoneCelecoxibPlacebo
Started5551
Treated5348
Completed47
Not completed5144
Withdrew: Adverse event30
Withdrew: Lack of efficacy611
Withdrew: Lost to follow-up11
Withdrew: Reason not specified20
Withdrew: Withdrawal by subject51
Withdrew: Study terminated by the sponsor3431

Outcome measures

PrimaryTime to Disease Progression

Time to disease progression was defined as the time from randomization to the earliest occurrence of one or more of the following events: 1. Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps); or 2. Diagnosis of colorectal malignancy (ColMal).

Time frame:
5 years
Reported as:
Mean · years
Time to Disease Progression
yearsCelecoxibPlacebo
Time to Disease Progression2.2 ± 1.081.8 ± 1.30
SecondaryTime to Treatment Failure

Time to treatment failure was defined as time from randomization to the earliest occurrence of one or more of the following: * Appearance of ≥20 polyps (\>2 mm in size) at any colonoscopy during the study (Polyps), or * Diagnosis of colorectal malignancy (ColMal), or * Treatment related dropout (DO). The treatment related dropout was defined as insufficient clinical response, progression of disease, death, adverse event, treatment-related laboratory abnormality, subject no longer willing to participate in study, and other reasons that might be related to treatment as determined by treating physicians in a blind fashion before database release.

Time frame:
5 years
Reported as:
Mean · years
Time to Treatment Failure
yearsCelecoxibPlacebo
Time to Treatment Failure2.0 ± 1.121.7 ± 1.30
SecondaryTotal Number of Colorectal Polyps

Total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5 cumulatively. Weighted total number of colorectal polyps over Years 1 - 5 cumulatively was defined as the total number of colorectal polyps \>2 mm in size, that were detected over Years 1 - 5, divided by the number of colonoscopies that the participant had during the study.

Time frame:
Years 1 - 5
Reported as:
Mean · polyps
Total Number of Colorectal Polyps
polypsCelecoxibPlacebo
Year 1 (N: 27, 30)3.0 ± 2.688.1 ± 7.32
Year 2 (N: 21, 25)8.8 ± 6.6313.7 ± 10.51
Year 3 (N: 16, 14)13.4 ± 11.3122.3 ± 11.74
Year 4 (N: 8, 7)18.6 ± 17.6536.4 ± 22.50
Year 5 (N: 2, 2)30.5 ± 21.9246.5 ± 34.65
Years 1 - 5 cumulatively (N: 33, 36)4.3 ± 3.588.6 ± 7.12
SecondaryColorectal Polyp Burden

The polyp burden was defined as the sum of the largest diameters of all polyps (\>2 mm in size) over Years 1 - 5 cumulatively. Weighted colorectal polyp burden over Years 1 - 5 cumulatively was defined as the polyp burden over Years 1 - 5 divided by the number of colonoscopies that the participant had during the study.

Time frame:
Years 1 - 5
Reported as:
Mean · mm
Colorectal Polyp Burden
mmCelecoxibPlacebo
Year 1 (N: 27, 30)4.0 ± 1.974.2 ± 2.05
Year 2 (N: 21, 25)6.9 ± 2.288.1 ± 4.06
Year 3 (N: 16, 14)9.6 ± 3.1411.6 ± 4.05
Year 4 (N: 8, 7)12.9 ± 3.3118.7 ± 5.88
Year 5 (N: 2, 2)20.0 ± 7.0720.0 ± 4.24
Year 1 - 5 cumulatively (N: 33, 36)4.1 ± 1.684.3 ± 1.61

Adverse events

Collected over Events were reported from randomization through and including 30 calendar days after the last administration of the study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—3/53 (5.7%)36/53 (67.9%)
Placebo—0/48 (0%)30/48 (62.5%)
Most frequent serious events
Most frequent serious events
EventCelecoxibPlacebo
Periorbital cellulitisInfections and infestations1/530/48
PneumoniaInfections and infestations1/530/48
DepressionPsychiatric disorders1/530/48
Most frequent other events
Showing 10 of 26
Most frequent other events
EventCelecoxibPlacebo
HeadacheNervous system disorders16/5314/48
Abdominal painGastrointestinal disorders9/5310/48
VomitingGastrointestinal disorders9/539/48
Upper respiratory tract infectionInfections and infestations4/539/48
Abdominal discomfortGastrointestinal disorders9/534/48
NauseaGastrointestinal disorders8/538/48
CoughRespiratory, thoracic and mediastinal disorders8/536/48
DiarrhoeaGastrointestinal disorders6/534/48
FatigueGeneral disorders6/534/48
InfluenzaInfections and infestations6/531/48

Baseline characteristics

The intent-to-treat (ITT) population (N: 106) consisted of all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether the participants received any study drug or received a different drug from that to which they were randomized.

Age, Continuous
Age, Continuous(years)CelecoxibPlaceboTotal
Mean12.6 ± 2.212.2 ± 1.812.4 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)CelecoxibPlaceboTotal
Female292857
Male262349
08

Study locations

43 sites
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68114, United States
  • Pfizer Investigational Site
    New York, New York 10017, United States
  • Pfizer Investigational Site
    New York, New York 10022, United States
  • Pfizer Investigational Site
    New York, New York 10065, United States
  • Pfizer Investigational Site
    Chagrin Falls, Ohio 44136, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45229, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44122, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Elyria, Ohio 44035, United States
  • Pfizer Investigational Site
    Independence, Ohio 44131, United States
  • Pfizer Investigational Site
    Lakewood, Ohio 44107, United States
  • Pfizer Investigational Site
    Lorain, Ohio 44053, United States
  • Pfizer Investigational Site
    Solon, Ohio 44138, United States
  • Pfizer Investigational Site
    Strongsville, Ohio 44136, United States
  • Pfizer Investigational Site
    Westlake, Ohio 44145, United States
  • Pfizer Investigational Site
    Willoughby Hills, Ohio 44094, United States
  • Pfizer Investigational Site
    Wooster, Ohio 44691, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Houston, Texas 77030-4990, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84112, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84132, United States
  • Pfizer Investigational Site
    Bruxelles, 1200, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Praha 5, 150 06, Czechia
  • Pfizer Investigational Site
    Praha, 150 06, Czechia
  • Pfizer Investigational Site
    Shatin, New Territories 0, Hong Kong
  • Pfizer Investigational Site
    Hong Kong, 150001, Hong Kong
  • Pfizer Investigational Site
    Miskolc, 3501, Hungary
  • Pfizer Investigational Site
    Haifa, 31096, Israel
  • Pfizer Investigational Site
    M.P. Lower Galilee, 15208, Israel
  • Pfizer Investigational Site
    Petach Tikvah 49202, Israel
  • Pfizer Investigational Site
    Tel Aviv, 64239, Israel
  • Pfizer Investigational Site
    Roma, 00144, Italy
  • Pfizer Investigational Site
    Siena, 53100, Italy
  • Pfizer Investigational Site
    Rio Piedras, 00935, Puerto Rico
  • Pfizer Investigational Site
    Bratislava, 833 40, Slovakia
  • Pfizer Investigational Site
    Cape Town, Western Cape, South Africa 7925, South Africa
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Stockholm, 17176, Sweden
  • Pfizer Investigational Site
    Donetsk, 83052, Ukraine
  • Pfizer Investigational Site
    Harrow, Middlesex, England HA1 3UJ, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2008
First posted
Jan 3, 2008
Start
Sep 2006
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Nov 2, 2014
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00585312
Responsible party
Sponsor
First posted
Jan 3, 2008
Start date
Sep 2006
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Nov 2, 2014
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion